Neoadjuvant selpercatinib for advanced medullary thyroid cancer-Reference-Cited by-同舟云学术

Neoadjuvant selpercatinib for advanced medullary thyroid cancer

Published:2020-11-09 Issue:1 Volume:43 Page:
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Jozaghi Yelda¹^ORCID,Zafereo Mark¹^ORCID,Williams Michelle D.²,Gule‐Monroe Maria K.³,Wang Jennifer¹^ORCID,Grubbs Elizabeth G.⁴,Vaporciyan Ara⁵,Hu Mimi I.⁶,Busaidy Naifa⁶,Dadu Ramona⁶,Waguespack Steven G.⁶,Subbiah Vivek⁷,Cabanillas Maria⁶^ORCID

Affiliation:

1. Department of Head and Neck Surgery The University of Texas M. D. Anderson Cancer Center Houston Texas USA

2. Department of Pathology The University of Texas M. D. Anderson Cancer Center Houston Texas USA

3. Department of Diagnostic Radiology The University of Texas M. D. Anderson Cancer Center Houston Texas USA

4. Department of Surgical Oncology The University of Texas M. D. Anderson Cancer Center Houston Texas USA

5. Department of Thoracic and Cardiovascular Surgery The University of Texas M. D. Anderson Cancer Center Houston Texas USA

6. Department of Endocrine Neoplasia and Hormonal Disorders The University of Texas M. D. Anderson Cancer Center Houston Texas USA

7. Department of Investigational Cancer Therapeutics The University of Texas M. D. Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.26527

Reference24 articles.

1. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

2. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.

3. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC

4. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours

5. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect and Safety of Apatinib as Neoadjuvant Therapy in Locally Advanced Differentiated Thyroid Cancer: A Phase 2 Trial;Journal of the Endocrine Society;2024-07-12

2. Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment—Implications for Systemic Treatment;Cancers;2024-06-22

3. Insights into highly selective RET inhibitors in medullary thyroid cancer;Current Opinion in Endocrine and Metabolic Research;2024-06

4. Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B;JCO Precision Oncology;2024-05

5. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades;The Journal of Clinical Endocrinology & Metabolism;2024-03-04